Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating lipopolysaccharide/D-aminogalactose induced liver injury

A technology for galactosamine and liver damage, which is applied in the field of clinical medicine and can solve problems such as unclear effects of liver damage

Inactive Publication Date: 2017-06-13
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The object of the present invention is to provide a drug for the treatment of lipopolysaccharide / D-galactosamine-induced liver injury, aiming to solve the problem that the effect of forsythiaside A on lipopolysaccharide / D-galactosamine-induced liver injury is still unclear question

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating lipopolysaccharide/D-aminogalactose induced liver injury
  • Medicine for treating lipopolysaccharide/D-aminogalactose induced liver injury
  • Medicine for treating lipopolysaccharide/D-aminogalactose induced liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] In order to make the object, technical solution and advantages of the present invention more clear, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0021] The application principle of the present invention will be described in detail below in conjunction with the accompanying drawings.

[0022] like figure 1 As shown, the method for constructing a model of a drug for verifying the treatment of lipopolysaccharide / D-galactosamine-induced liver injury provided by the embodiments of the present invention includes the following steps:

[0023] S101: Seventy-five mice were randomly divided into five groups, each group containing 15 mice;

[0024] S102: Group I, normal control group, mice received the same amount of PBS; Group II, model control group, mice received GalN800 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating lipopolysaccharide / D-aminogalactose (LPS / GalN) induced liver injury. The medicine for treating lipopolysaccharide / D-aminogalactose (LPS / GalN) induced liver injury is forsythiaside A. The forsythiaside A is capable of alleviating liver pathological injury induced by lipopolysaccharide / D-aminogalactose (LPS / GalN), reducing content of malonaldehyde (MDA) and serum ALT (Alanine Aminotransferase) and AST (Aspartate Amino Transferase) levels. In addition, the forsythiaside A is capable of inhibiting NF-chiB activation, serum TNF-alpha and liver TNF-alpha levels caused by LPS / GalN. In addition, the forsythiaside A is capable of increasing expression of Nrf2 and haem oxygenase 1. Results show that the protection function of the forsythiaside A on LPS / GalN induced liver injury is achieved by activating Nrf2 and inhibiting NF-chiB activation.

Description

technical field [0001] The invention belongs to the technical field of clinical medicine, and in particular relates to a medicine for treating liver damage induced by lipopolysaccharide / D-galactosamine (LPS / GalN). Background technique [0002] In liver failure, the chances of endotoxemia and sepsis are significantly higher, and the lack of effective drugs often leads to high mortality. Therefore, there is an urgent need to develop targeted and effective drug therapies for liver injury. Mice with acute liver injury induced by lipopolysaccharide and D-galactosamine are a widely used model of liver injury. It has been used for many years in preliminary pharmacological studies of potential therapeutic agents. Galactosamine is a hepatotoxic agent, and the hepatotoxicity is mainly through inhibition of RNA and protein synthesis in hepatocytes. Lipopolysaccharide is an endotoxin that can induce the production of inflammatory cytokines. These pro-inflammatory mediators can lead ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7032A61P1/16A61K49/00A61K31/739A61K31/7008
CPCA61K31/7032A61K31/7008A61K31/739A61K49/0008A61K2300/00
Inventor 潘陈为陈未来周光耀金玲湘李杰郑毅诸葛璐方佩佩
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com